View Older Stories View More Recent Stories

Nov 11, 2019 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results
Nov 8, 2019 08:06AM Arrowhead Pharmaceuticals Corp (ARWR), Janssen Pharmaceuticals, Inc. Announce Phase 2 Clinical Data for Investigational Hepatitis B Regimens
Nov 8, 2019 08:00AM Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
Oct 31, 2019 12:18PM Arrowhead Pharmaceuticals Corp (ARWR) Presents Preclinical Data on ARO-ENaC at NACFC
Oct 31, 2019 12:15PM Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference
Oct 18, 2019 07:30AM Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics
Sep 30, 2019 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences
Sep 20, 2019 04:00PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Sep 16, 2019 06:20AM Arrowhead Pharmaceuticals (ARWR) Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
Sep 16, 2019 03:00AM Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
Aug 30, 2019 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences
Aug 28, 2019 07:41AM Arrowhead Pharmaceuticals Corp (ARWR) Collaborator Janssen Commences REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection
Aug 28, 2019 07:30AM Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection
Aug 8, 2019 07:40AM Arrowhead Pharmaceuticals Corp (ARWR) Reports First Patient Dosing in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Aug 8, 2019 07:30AM Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Aug 5, 2019 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results
Jul 24, 2019 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results
Jul 16, 2019 04:10PM Arrowhead Pharmaceuticals Corp (ARWR) Granted Orphan Drug Designation for ARO-ANG3
Jul 16, 2019 04:00PM Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3
Jul 8, 2019 07:30AM Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference
Jun 27, 2019 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Granted Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease
Jun 27, 2019 07:30AM Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease
Jun 21, 2019 06:45PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Jun 21, 2019 07:31AM Arrowhead Pharmaceuticals (ARWR) Confirms it Received Orphan Drug Designation for ARO-APOC3
Jun 21, 2019 07:30AM Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3
May 31, 2019 04:00PM Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences
May 8, 2019 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results
May 2, 2019 07:30AM Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences
Apr 24, 2019 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results
Apr 24, 2019 07:39AM Arrowhead Pharmaceuticals Corp (ARWR) Commences Triple Combination Cohort in Chronic HBV Patients; Reports $25M Milestone Payment from Janssen
Apr 24, 2019 07:30AM Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
Apr 15, 2019 07:36AM Arrowhead Pharma (ARWR) Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Apr 15, 2019 07:30AM Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Apr 12, 2019 12:46PM Arrowhead (ARWR) Presents Clinical Data on JNJ-3989 (ARO-HBV) at EASL
Apr 12, 2019 12:45PM Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™
Apr 12, 2019 06:00AM Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™
Mar 29, 2019 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Mar 18, 2019 07:34AM Arrowhead Pharmaceuticals Corp (ARWR) Reports IND Filing for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Mar 18, 2019 07:30AM Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Mar 11, 2019 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Commences Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Mar 11, 2019 07:30AM Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Mar 1, 2019 07:30AM Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences
Feb 7, 2019 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
Jan 24, 2019 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results
Jan 7, 2019 07:40AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Filing of Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Jan 7, 2019 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Reports First Patient Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
Jan 7, 2019 07:30AM Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
Jan 7, 2019 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Dec 17, 2018 06:06PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Dec 11, 2018 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results
View More Recent Stories View Older Stories